NEW ERA IN THE WAR ON CANCER
Revolutionary treatment that will save thousands hailed as ‘biggest breakthrough since chemotherapy’
A CANCER treatment that teaches the body to attack tumours will save the lives of tens of thousands of patients, researchers claim.
Experts believe it could be the biggest step forward since chemotherapy and could replace it within five years.
The treatment is particularly effective against some of the deadliest types of the disease including lung and skin cancer. Trials show that it has eradicated tumours in patients who were expected to survive for only a few months and they are now leading normal lives.
Called immunotherapy, it works by training the immune system to attack cancerous cells. As well as
lung and skin cancer, it has been hugely effective against kidney, bladder, and head and neck cancers, research from a number of key trials presented at the American Society for Clinical Oncology conference in Chicago shows.
These are some of the most aggressive types which are extremely difficult to treat and, together, claim the lives of 54,000 Britons every year.
In one British trial, patients with advanced skin cancer who would have been declared terminally ill are now back at work and are predicted to live until old age. Some may never need treatment again, others just require topup sessions every few weeks or months.
Professor Peter Johnson, director of medical oncology at Cancer Research UK, said: ‘The evidence suggests we are at the beginning of a whole new era for cancer treatments. Not for every type of cancer, but for some of the ones we have struggled with the most.
‘We are hoping that in many cases these effects will be maintained in the long term, possibly leading to cures for some.’
Professor Roy Herbst, chief of medical
‘More important than
chemotherapy’
oncology at Yale Cancer Centre in the US, said that immunotherapy could replace chemotherapy as the ‘standard treatment’ for cancer within the next five years.
‘I think we are seeing a paradigm shift in the way oncology is being treated,’ he said. ‘You can see a response as quickly as a couple of weeks. Some patients have amazing survival.’
Roger Perlmutter, president of research at the drugs firm Merck, which makes one of the main types of immunotherapy treatments, said: ‘Immune manipulation may turn out to be an even more important intervention than chemotherapy was – maybe the most important ever.’
Although our immune system is trained to fight infections and cancer, some tumours are able to develop protective shields, meaning that the body’s immune system, chemotherapy and other drugs are all ineffective.
But immunotherapy breaks down these shields and trains our body how to attack the tumours. Treatments are given in a drip every few weeks and typically cost around £100,000 per patient a year. Some types are already available on the NHS but others are awaiting approval by European regulators.
One trial, involving 950 British patients with advanced skin cancer, showed that for 60 per cent the tumours had either shrunk or been brought under control.
Dr James Larkin, a consultant at the Royal Marsden Hospital in London, who is overseeing it, said it was a ‘game changer’. Although the trial began only two years ago, he said he hoped many would survive until old age.
‘We have to be cautious about using the word cure but we’ve got patients who are basically free of melanoma (skin cancer) now, they’re leading normal lives,’ he said.
The treatment does not work for all patients and some trials showed it was effective in only 25-50 per cent because it depends on the characteristics of their tumour. But results from the skin cancer trial showed that combining two types of immunotherapy treatment benefited many more patients. So while one type was effective for 15 per cent of patients, two types combined worked for 60 per cent.
Experts hope that for all types of cancer, immunotherapy will be effective for at least half of patients.
The treatment is currently available for some NHS patients with skin cancer and the researchers argue its use should be widened for other cancers as soon as possible. The sideeffects are less severe than for chemotherapy but include rashes, sickness and tiredness.
Chemotherapy was not routinely used on cancer patients until the 1960s and 1970s. It causes extreme tiredness, sickness and hair loss and makes patients susceptible to infection, meaning many patients stop chemotherapy early even if it could prolong their lives.
One who has benefited from the new treatment is former college teacher Vicky Brown, 61, who was diagnosed with skin cancer in 2006 which returned and spread to her breasts and lungs. She was told in 2013 that she might live for only a few more months.
But she took part in the clinical trials at the Royal Marsden which began that August and within weeks the tumours had disappeared completely. Although it returned again, it was again eradicated by immunotherapy. It has come back a third time and doctors plan to use the same technique.
Mrs Brown, from Cardiff, said: ‘It felt like a miracle drug. It has given me at least two years of life to enjoy – and hopefully many more.’